Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study - Murakami, Kazunari; Sakurai, Yuuichi; Shiino, Madoka; Funao, Nobuo; Nishimura, Akira; Asaka, Masahiro (Gut, 2016)
Keywords: Acids; Adult; Amoxicillin - administration & dosage; Amoxicillin - adverse effects; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Breath Tests - methods; Clarithromycin - administration & dosage; Clarithromycin - adverse effects; Clinical medicine; Competition; Double-Blind Method; Double-blind studies; Drug Administration Schedule; Drug dosages; Drug Monitoring - methods; Drug Therapy, Combination - methods; Electrocardiography; Enzymes; Female; Gastric cancer; Helicobacter Infections - complications; Helicobacter Infections - diagnosis; Helicobacter Infections - drug therapy; Helicobacter Pylori; Helicobacter pylori - drug effects; Helicobacter pylori - isolation & purification; Humans; Lansoprazole - administration & dosage; Lansoprazole - adverse effects; Lymphoma; Male; Medical laboratories; Metronidazole - administration & dosage; Metronidazole - adverse effects; Middle Aged; Peptic Ulcer - diagnosis; Peptic Ulcer - drug therapy; Peptic Ulcer - etiology; Potassium; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - adverse effects; Protons; Pyrroles - administration & dosage; Pyrroles - adverse effects; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Treatment Outcome; Ulcers; Japan; HELICOBACTER PYLORI - TREATMENT; CLINICAL TRIALS; ANTIBIOTIC THERAPY; HELICOBACTER PYLORI INFECTION